Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
Page 2

The organizers of the program hopes for the outcome of the project to have a substantial impact bioequivalence policy development for generic orally inhaled products.

Furthermore, the initiatives included under this funding opportunity announcement also intends to achieve the following objectives:

a) Develop a quality-by-design tool that could be utilized to improve the performance of orally inhaled drugs during the product development phase.

b) Determine accurate dose predictions.

c) Set clinical relevant aerodynamic particle size distribution specifications to ensure product quality, for these drug/device combination products.

To support these initiatives, the USFDA is ready to administer funds in the amount of $150,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The Department of Health and Human Services, the mother agency funding the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program, is the nation's leading agency for protecting the health of all Americans and providing fundamental human services to all.

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Identifying Heart, Lung, and Blood Disease-Causing Variants
The National Institutes of Health has formed a partnership with the National Heart, Lung, and Blood Institute to establish a program that aims to Identify Heart, Lung, and Blood Disease-Causing Variants.

---

2012 Tuberous Sclerosis Complex Clinical Trial Award Program
In line with this mission, the United States Department of Defense has recently established the 2012 Tuberous Sclerosis Complex Clinical Trial Award Program in an attempt to financially support the studies regarding the promotion innovative research focused on decreasing the clinical impact of tuberous sclerosis complex (TSC).

---

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
In this capacity, the Food and Drug Administration has recently established the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program in an attempt to study the effects of various physicochemical properties of ophthalmic suspensions and emulsions on ocular bioavailability.

---

Health Care Innovation Challenge
The Centers for Medicare and & Medicaid Services has recently established the Health Care Innovation Challenge in an attempt to solicit proposals to establish interesting new models of service delivery that can potentially deliver the three-part aim of better health, better health care, and finally, lower costs through the improved quality of Medicare, Medicaid, and Children's Health Insurance Program.

---